| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 474.0K | $234.39M | -18,410 | |
| Dir | Taub Rebecca | 455.8K | $225.41M | -240 |
| Dir | 357.8K | $176.94M | - | |
| Dir | 211.7K | $104.68M | -24,800 | |
| ? | 198.2K | $98.03M | - | |
| ? | BAKER BROS. ADVISORS LP | 188.8K | $93.38M | - |
| Dir | FRIEDMAN PAUL A | 187.2K | $92.55M | - |
| CEO | 150.1K | $74.21M | - | |
| CEO | Sibold William John | 102.5K | $50.67M | - |
| Dir | 23.7K | $11.72M | - | |
| Dir | Levy Richard S | 21.2K | $10.48M | - |
| CFO | 14.6K | $7.23M | - | |
| Dir | BATE KENNETH | 12.6K | $6.24M | - |
| Other | Huntsman Carole | 12.0K | $5.93M | - |
| Other | 11.1K | $5.49M | - | |
| VP | Waltermire Robert E. | 10.6K | $5.22M | - |
| CFO | Dier Mardi | 10.4K | $5.16M | - |
| Other | Kelley Shannon T | 10.0K | $4.95M | - |
| Dir | 8.1K | $4.00M | - | |
| Other | Soergel David | 7.5K | $3.73M | - |
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| 2025-02-27 | BATE KENNETH | Director | Sale+OE | 19,762 | $356.47 | $7,044,546.34 | -19.6% | → |
| 2025-02-27 | Daly James M | Director | Sale+OE | 14,700 | $347.38 | $5,106,439.21 | -42.8% | → |
| 2025-01-24 | Taub Rebecca | Pres., R&D, and CMO | Sell | 648 | $335.24 | $217,235.52 | -0.1% | → |
| 2025-01-24 | Sibold William John | President and CEO | Sell | 1,584 | $335.24 | $531,020.16 | -2.8% | → |
| 2025-01-24 | Huntsman Carole | Chief Commercial Officer | Sell | 347 | $335.24 | $116,328.28 | -3.2% | → |
| 2025-01-24 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 103 | $335.24 | $34,529.72 | -2.0% | → |
| 2025-01-17 | Taub Rebecca | Pres., R&D, and CMO | Sell | 1,689 | $273.41 | $461,789.49 | -0.4% | → |
| 2025-01-17 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 442 | $273.41 | $120,847.22 | -8.0% | → |
| 2025-01-17 | Kelley Shannon T | General Counsel | Sell | 277 | $273.41 | $75,734.57 | -3.5% | → |
| 2024-12-03 | CRAVES FRED B | Director | Sell | 3,600 | $315.31 | $1,135,121.70 | -13.8% | → |
| 2024-11-25 | CRAVES FRED B | Director | Sell | 3,400 | $350.30 | $1,191,028.02 | -10.1% | → |
| 2024-11-21 | Huntsman Carole | Chief Commercial Officer | Sell | 688 | $316.92 | $218,040.96 | -6.0% | → |
| 2024-11-07 | Levy Richard S | - | Sale+OE | 5,000 | $350.00 | $1,750,000.00 | -31.2% | → |
| 2024-11-01 | Levy Richard S | - | Sale+OE | 5,000 | $300.94 | $1,504,703.41 | -9.5% | → |
| 2024-09-09 | Sibold William John | President and CEO | Sell | 6,363 | $243.83 | $1,551,490.29 | -10.2% | → |
| 2024-06-14 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale+OE | 1,900 | $280.00 | $532,000.00 | -25.7% | → |
| 2024-06-12 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sale+OE | 2,000 | $285.00 | $570,000.00 | -26.7% | → |
| 2024-05-21 | Waltermire Robert E. | Senior VP, Chief Pharma Dev. | Sell | 1,036 | $231.34 | $239,668.24 | -15.9% | → |
| 2024-05-14 | CRAVES FRED B | - | Sale+OE | 22,489 | $212.88 | $4,787,404.04 | -0.5% | → |
| 2024-04-08 | FRIEDMAN PAUL A | - | Sale+OE | 12,912 | $244.57 | $3,157,897.67 | -1.6% | → |
| 2024-04-08 | Taub Rebecca | Pres., R&D, and CMO | Sale+OE | 2,452 | $246.24 | $603,770.73 | -0.1% | → |